SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference

Wednesday, July 31, 2019 Press Release
Email Print This Page Comment bookmark
Font : A-A+

JERSEY CITY, N.J., July 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August

7, 2019 at 5:00 p.m. ET.

A live webcast of the presentation will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species. For more information, visit www.scynexis.com.

CONTACT: 

Investor RelationsHeather SavelleArgot PartnersTel: 212-600-1902heather@argotpartners.com

Media RelationsGeorge E. MacDougallMacDougallTel: 781-235-3093george@macbiocom.com

Cision View original content:http://www.prnewswire.com/news-releases/scynexis-inc-to-present-at-the-39th-annual-canaccord-genuity-global-growth-conference-300893615.html

SOURCE SCYNEXIS, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store